Original Research
Published on 05 Aug 2022
MAFG-AS1 is a prognostic biomarker and facilitates prostate cancer progression
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.856580
- 2,095 views
- 5 citations
Type at least 3 characters
1,560 articles
Articles
Review
Published on 03 Aug 2022
Non-muscle invasive bladder cancer biomarkers beyond morphology
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.947446
- 3,793 views
- 5 citations
Original Research
Published on 03 Aug 2022
Elevated expression of LIF predicts a poor prognosis and promotes cell migration and invasion of clear cell renal cell carcinoma
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.934128
- 3,667 views
- 4 citations
Case Report
Published on 03 Aug 2022
Case report: Important considerations for a renal mass on a solitary kidney in an adult with history of childhood wilms tumor
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.971341
- 1,793 views
- 1 citation
Original Research
Published on 01 Aug 2022
ELAVL1 promotes prostate cancer progression by interacting with other m6A regulators
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.939784
- 4,395 views
- 10 citations
Original Research
Published on 01 Aug 2022
Multi-omics analysis of expression and prognostic value of NSUN members in prostate cancer
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.965571
- 5,887 views
- 19 citations
Case Report
Published on 01 Aug 2022
What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.951348
- 3,034 views
- 2 citations
Original Research
Published on 01 Aug 2022
C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.918993
- 2,909 views
- 4 citations
Original Research
Published on 29 Jul 2022
Indications for nerve-sparing surgery for radical prostatectomy: Results from a single-center study
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.896033
- 3,477 views
- 2 citations
Case Report
Published on 28 Jul 2022
Case report: A case of neoadjuvant immunotherapy in combination with the Yang–Monti technique for the treatment of ureteral carcinoma after radical cystectomy and left radical nephroureterectomy
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.889028
- 1,494 views
- 1 citation
Original Research
Published on 28 Jul 2022
Pathological characteristics and predictive factors of prostate biopsy in patients with serum PSA levels between 0 and 4.0 ng/ml
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.957892
- 1,942 views
Case Report
Published on 28 Jul 2022
Case report: An ectopic adrenocortical adenoma in the renal sinus
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.934862
- 2,131 views
- 2 citations
Original Research
Published on 28 Jul 2022
Methods for Establishing a Renal Cell Carcinoma Tumor Spheroid Model With Immune Infiltration for Immunotherapeutic Studies
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.898732
- 5,084 views
- 9 citations
Editorial
Published on 27 Jul 2022
Editorial: Immunotherapy in renal cell carcinoma
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.945510
- 2,306 views
Editorial
Published on 26 Jul 2022
Editorial: in vitro and in vivo non-clinical models of kidney cancers
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.987682
- 1,428 views
Systematic Review
Published on 22 Jul 2022
Detection rate of fluorine-18 prostate-specific membrane antigen-1007 PET/CT for prostate cancer in primary staging and biochemical recurrence with different serum PSA levels: A systematic review and meta-analysis
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.911146
- 2,451 views
- 7 citations